Rous Sarcoma Virus (RSV) and Cancer
Pharmacokinetics in Pediatric Patients: Drug Distribution
Single Nucleotide Polymorphisms-SNPs
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Factors Affecting the Risk of Infection
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Oct 28, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Dusan Bogunovic1, Miriam Merad2
1Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center of Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The world population is experiencing SARS-CoV-2 infections. While severe COVID-19 affects adults, multisystem inflammatory disorder impacts children, prompting a discussion of known and unknown features in pediatric populations.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: